Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 345

1.

The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status: A Study By the International Genetic Consortium for Colorectal Liver Metastasis.

Margonis GA, Amini N, Buettner S, Kim Y, Wang J, Andreatos N, Wagner D, Sasaki K, Beer A, Kamphues C, Morioka D, Løes IM, Imai K, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Burkhart R, Endo I, Baba H, Mischinger HJ, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ.

Ann Surg. 2019 Aug 5. doi: 10.1097/SLA.0000000000003504. [Epub ahead of print]

PMID:
31389831
2.

Constitutional Mosaic Epimutations - a hidden cause of cancer?

Lønning PE, Eikesdal HP, Løes IM, Knappskog S.

Cell Stress. 2019 Mar 22;3(4):118-135. doi: 10.15698/cst2019.04.183. Review.

3.

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC.

Røsland GV, Dyrstad SE, Tusubira D, Helwa R, Tan TZ, Lotsberg ML, Pettersen IKN, Berg A, Kindt C, Hoel F, Jacobsen K, Arason AJ, Engelsen AST, Ditzel HJ, Lønning PE, Krakstad C, Thiery JP, Lorens JB, Knappskog S, Tronstad KJ.

Cancer Metab. 2019 Jun 1;7:6. doi: 10.1186/s40170-019-0197-8. eCollection 2019.

4.

Prognostic Factors Change Over Time After Hepatectomy for Colorectal Liver Metastases: A Multi-institutional, International Analysis of 1099 Patients.

Margonis GA, Buettner S, Andreatos N, Wagner D, Sasaki K, Barbon C, Beer A, Kamphues C, Løes IM, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Cameron JL, Mischinger HJ, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ.

Ann Surg. 2019 Jun;269(6):1129-1137. doi: 10.1097/SLA.0000000000002664.

PMID:
31082912
5.

Human endotrophin as a driver of malignant tumor growth.

Bu D, Crewe C, Kusminski CM, Gordillo R, Ghaben AL, Kim M, Park J, Deng H, Xiong W, Liu XZ, Lønning PE, Halberg N, Rios A, Chang Y, Gonzalez A, Zhang N, An Z, Scherer PE.

JCI Insight. 2019 Mar 21;5. pii: 125094. doi: 10.1172/jci.insight.125094.

6.

BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only?

Lønning PE, Knappskog S.

Clin Epigenetics. 2018 Oct 22;10(1):128. doi: 10.1186/s13148-018-0566-0.

7.

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients.

Borgen E, Rypdal MC, Sosa MS, Renolen A, Schlichting E, Lønning PE, Synnestvedt M, Aguirre-Ghiso JA, Naume B.

Breast Cancer Res. 2018 Oct 16;20(1):120. doi: 10.1186/s13058-018-1049-0.

8.

The prognosis of colorectal cancer liver metastases associated with inflammatory bowel disease: An exploratory analysis.

Margonis GA, Buettner S, Andreatos N, Wagner D, Sasaki K, Galjart B, Kamphues C, Pawlik TM, Poultsides G, Kaczirek K, Lønning PE, Verhoef C, Kreis ME, Wolfgang CL, Weiss MJ.

J Surg Oncol. 2018 Dec;118(7):1074-1080. doi: 10.1002/jso.25251. Epub 2018 Sep 27.

PMID:
30261094
9.

Patterns of genomic evolution in advanced melanoma.

Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E, Myklebost O, Knappskog S, Lønning PE.

Nat Commun. 2018 Jul 10;9(1):2665. doi: 10.1038/s41467-018-05063-1.

10.

Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.

Margonis GA, Buettner S, Andreatos N, Kim Y, Wagner D, Sasaki K, Beer A, Schwarz C, Løes IM, Smolle M, Kamphues C, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Cameron JL, Burkhart RA, Gerger A, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ.

JAMA Surg. 2018 Jul 18;153(7):e180996. doi: 10.1001/jamasurg.2018.0996. Epub 2018 Jul 18.

11.

Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series.

Deshwar A, Margonis GA, Andreatos N, Barbon C, Wang J, Buettner S, Wagner D, Sasaki K, Beer A, Løes IM, Pikoulis E, Damaskos C, Garmpis N, Kamphues K, He J, Kaczirek K, Poultsides G, Lønning PE, Mischinger HJ, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ.

Anticancer Res. 2018 May;38(5):2891-2895.

PMID:
29715113
12.

Prognostic Factors Change Over Time After Hepatectomy for Colorectal Liver Metastases: A Multi-institutional, International Analysis of 1099 Patients.

Margonis GA, Buettner S, Andreatos N, Wagner D, Sasaki K, Barbon C, Beer A, Kamphues C, Løes IM, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Cameron JL, Mischinger HJ, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ.

Ann Surg. 2018 Jan 18. doi: 10.1097/SLA.0000000000002664. [Epub ahead of print]

PMID:
29351098
13.

White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk.

Lønning PE, Berge EO, Bjørnslett M, Minsaas L, Chrisanthar R, Høberg-Vetti H, Dulary C, Busato F, Bjørneklett S, Eriksen C, Kopperud R, Axcrona U, Davidson B, Bjørge L, Evans G, Howell A, Salvesen HB, Janszky I, Hveem K, Romundstad PR, Vatten LJ, Tost J, Dørum A, Knappskog S.

Ann Intern Med. 2018 Mar 6;168(5):326-334. doi: 10.7326/M17-0101. Epub 2018 Jan 16.

PMID:
29335712
14.

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, O'Regan R, Mouret-Reynier MA, Kalev D, Egle D, Csőszi T, Bordonaro R, Decker T, Tjan-Heijnen VCG, Blau S, Schirone A, Weber D, El-Hashimy M, Dharan B, Sellami D, Bachelot T.

Lancet Oncol. 2018 Jan;19(1):87-100. doi: 10.1016/S1470-2045(17)30688-5. Epub 2017 Dec 7. Erratum in: Lancet Oncol. 2018 Mar;19(3):e137.

PMID:
29223745
15.

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.

Cheang MCU, Bliss JM, Viale G, Speirs V, Palmieri C, Shaaban A, Lønning PE, Morden J, Porta N, Jassem J, van De Velde CJ, Rasmussen BB, Verhoeven D, Bartlett JMS, Coombes RC; PathIES Sub-Committee.

Breast Cancer Res Treat. 2018 Feb;168(1):169-178. doi: 10.1007/s10549-017-4543-7. Epub 2017 Nov 24.

16.

APOBEC3A/B deletion polymorphism and cancer risk.

Gansmo LB, Romundstad P, Hveem K, Vatten L, Nik-Zainal S, Lønning PE, Knappskog S.

Carcinogenesis. 2018 Feb 9;39(2):118-124. doi: 10.1093/carcin/bgx131.

17.

Divergent Activity of the Pseudogene PTENP1 in ER-Positive and Negative Breast Cancer.

Yndestad S, Austreid E, Skaftnesmo KO, Lønning PE, Eikesdal HP.

Mol Cancer Res. 2018 Jan;16(1):78-89. doi: 10.1158/1541-7786.MCR-17-0207. Epub 2017 Oct 11.

18.

The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells.

Huun J, Gansmo LB, Mannsåker B, Iversen GT, Sommerfelt-Pettersen J, Øvrebø JI, Lønning PE, Knappskog S.

Transl Oncol. 2017 Oct;10(5):806-817. doi: 10.1016/j.tranon.2017.07.006. Epub 2017 Aug 29.

20.

Genomic Evolution of Breast Cancer Metastasis and Relapse.

Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, Martincorena I, Alexandrov LB, Van Loo P, Haugland HK, Lilleng PK, Gundem G, Gerstung M, Pappaemmanuil E, Gazinska P, Bhosle SG, Jones D, Raine K, Mudie L, Latimer C, Sawyer E, Desmedt C, Sotiriou C, Stratton MR, Sieuwerts AM, Lynch AG, Martens JW, Richardson AL, Tutt A, Lønning PE, Campbell PJ.

Cancer Cell. 2017 Aug 14;32(2):169-184.e7. doi: 10.1016/j.ccell.2017.07.005.

21.

Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer.

Lønning PE.

JAMA Oncol. 2017 Aug 1;3(8):1140. doi: 10.1001/jamaoncol.2016.7123. No abstract available.

PMID:
28727878
22.

Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines.

Huun J, Lønning PE, Knappskog S.

Cell Death Discov. 2017 May 22;3:17026. doi: 10.1038/cddiscovery.2017.26. eCollection 2017.

23.

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.

Yndestad S, Austreid E, Svanberg IR, Knappskog S, Lønning PE, Eikesdal HP.

Oncotarget. 2017 Jun 20;8(25):41227-41241. doi: 10.18632/oncotarget.17167.

24.

Long-Term Follow-Up of the Intergroup Exemestane Study.

Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC.

J Clin Oncol. 2017 Aug 1;35(22):2507-2514. doi: 10.1200/JCO.2016.70.5640. Epub 2017 May 3.

25.

Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells.

Huun J, Gansmo LB, Mannsåker B, Iversen GT, Øvrebø JI, Lønning PE, Knappskog S.

BMC Cell Biol. 2017 Apr 17;18(1):17. doi: 10.1186/s12860-017-0134-z.

26.

High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function.

Yndestad S, Austreid E, Knappskog S, Chrisanthar R, Lilleng PK, Lønning PE, Eikesdal HP.

Breast Cancer Res Treat. 2017 May;163(1):177-190. doi: 10.1007/s10549-017-4160-5. Epub 2017 Feb 17.

27.

MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.

Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S.

BMC Cancer. 2017 Feb 3;17(1):97. doi: 10.1186/s12885-017-3094-y.

28.

Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy.

Kim J, de Sampaio PC, Lundy DM, Peng Q, Evans KW, Sugimoto H, Gagea M, Kienast Y, Amaral NSD, Rocha RM, Eikesdal HP, Lønning PE, Meric-Bernstam F, LeBleu VS.

JCI Insight. 2016 Dec 22;1(21):e90733. doi: 10.1172/jci.insight.90733.

29.

DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival.

Fleischer T, Klajic J, Aure MR, Louhimo R, Pladsen AV, Ottestad L, Touleimat N, Laakso M, Halvorsen AR, Grenaker Alnæs GI, Riis ML, Helland Å, Hautaniemi S, Lønning PE, Naume B, Børresen-Dale AL, Tost J, Kristensen VN.

Oncotarget. 2017 Jan 3;8(1):1074-1082. doi: 10.18632/oncotarget.13718.

30.

Prevalence of the CHEK2 R95* germline mutation.

Knappskog S, Leirvaag B, Gansmo LB, Romundstad P, Hveem K, Vatten L, Lønning PE.

Hered Cancer Clin Pract. 2016 Sep 27;14:19. eCollection 2016.

31.

MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer.

Helwa R, Gansmo LB, Romundstad P, Hveem K, Vatten L, Ryan BM, Harris CC, Lønning PE, Knappskog S.

Sci Rep. 2016 Sep 14;6:33153. doi: 10.1038/srep33153.

32.

Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection.

Sveen A, Løes IM, Alagaratnam S, Nilsen G, Høland M, Lingjærde OC, Sorbye H, Berg KC, Horn A, Angelsen JH, Knappskog S, Lønning PE, Lothe RA.

PLoS Genet. 2016 Jul 29;12(7):e1006225. doi: 10.1371/journal.pgen.1006225. eCollection 2016 Jul.

33.

Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.

Flågeng MH, Larionov A, Geisler J, Knappskog S, Prestvik WS, Bjørkøy G, Lilleng PK, Dixon JM, Miller WR, Lønning PE, Mellgren G.

J Steroid Biochem Mol Biol. 2017 Jan;165(Pt B):228-235. doi: 10.1016/j.jsbmb.2016.06.011. Epub 2016 Jun 22.

PMID:
27343990
34.

Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate.

Gansmo LB, Vatten L, Romundstad P, Hveem K, Ryan BM, Harris CC, Knappskog S, Lønning PE.

Oncotarget. 2016 May 10;7(19):28637-46. doi: 10.18632/oncotarget.8705.

35.

Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.

Løes IM, Immervoll H, Sorbye H, Angelsen JH, Horn A, Knappskog S, Lønning PE.

Int J Cancer. 2016 Aug 1;139(3):647-56. doi: 10.1002/ijc.30089. Epub 2016 Apr 4.

36.

Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel.

Tambe M, Pruikkonen S, Mäki-Jouppila J, Chen P, Elgaaen BV, Straume AH, Huhtinen K, Cárpen O, Lønning PE, Davidson B, Hautaniemi S, Kallio MJ.

Oncotarget. 2016 Mar 15;7(11):12267-85. doi: 10.18632/oncotarget.7860.

37.

Comments on paper: "Quantitative determination of estrone by liquid chromatography-tandem mass spectrometry in subcutaneous adipose tissue from the breast in postmenopausal women" by Vihma et al.

Lønning PE.

J Steroid Biochem Mol Biol. 2016 May;159:72. doi: 10.1016/j.jsbmb.2016.02.026. Epub 2016 Feb 27. No abstract available.

PMID:
26925928
38.

The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer.

Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Dørum A, Birkeland E, Hveem K, Romundstad P, Vatten L, Lønning PE, Knappskog S.

Tumour Biol. 2016 Aug;37(8):10697-702. doi: 10.1007/s13277-016-4940-2. Epub 2016 Feb 11.

39.

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer.

Dowsett M, Lønning PE, Davidson NE.

J Clin Oncol. 2016 May 10;34(14):1580-3. doi: 10.1200/JCO.2015.62.3728. Epub 2016 Jan 4. No abstract available.

PMID:
26729430
40.

DNA methylation subgroups in melanoma are associated with proliferative and immunological processes.

Lauss M, Ringnér M, Karlsson A, Harbst K, Busch C, Geisler J, Lønning PE, Staaf J, Jönsson G.

BMC Med Genomics. 2015 Nov 6;8:73. doi: 10.1186/s12920-015-0147-4.

41.

MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung-, and prostate cancer risk.

Gansmo LB, Romundstad P, Birkeland E, Hveem K, Vatten L, Knappskog S, Lønning PE.

Cancer Med. 2015 Dec;4(12):1901-7. doi: 10.1002/cam4.555. Epub 2015 Oct 16.

42.

Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer.

Flågeng MH, Knappskog S, Gjerde J, Lønning PE, Mellgren G.

PLoS One. 2015 Aug 6;10(8):e0134351. doi: 10.1371/journal.pone.0134351. eCollection 2015.

43.

Subclonal diversification of primary breast cancer revealed by multiregion sequencing.

Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, Aas T, Alexandrov LB, Larsimont D, Davies H, Li Y, Ju YS, Ramakrishna M, Haugland HK, Lilleng PK, Nik-Zainal S, McLaren S, Butler A, Martin S, Glodzik D, Menzies A, Raine K, Hinton J, Jones D, Mudie LJ, Jiang B, Vincent D, Greene-Colozzi A, Adnet PY, Fatima A, Maetens M, Ignatiadis M, Stratton MR, Sotiriou C, Richardson AL, Lønning PE, Wedge DC, Campbell PJ.

Nat Med. 2015 Jul;21(7):751-9. doi: 10.1038/nm.3886. Epub 2015 Jun 22.

44.

Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.

Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE.

Mol Oncol. 2015 Oct;9(8):1553-64. doi: 10.1016/j.molonc.2015.04.008. Epub 2015 May 8.

45.

Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.

Speirs V, Viale G, Mousa K, Palmieri C, Reed SN, Nicholas H, Cheang M, Jassem J, Lønning PE, Kalaitzaki E, van de Velde CJ, Rasmussen BB, Verhoeven DM, Shaaban AM, Bartlett JM, Bliss JM, Coombes RC; PathIES Sub-Committee.

Ann Oncol. 2015 Sep;26(9):1890-7. doi: 10.1093/annonc/mdv242. Epub 2015 May 22.

46.

Normal breast tissue estrogen levels.

Lønning PE.

Maturitas. 2015 Jun;81(2):327. doi: 10.1016/j.maturitas.2015.03.005. Epub 2015 Mar 16. No abstract available.

PMID:
25864130
47.

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.

Lauss M, Haq R, Cirenajwis H, Phung B, Harbst K, Staaf J, Rosengren F, Holm K, Aine M, Jirström K, Borg Å, Busch C, Geisler J, Lønning PE, Ringnér M, Howlin J, Fisher DE, Jönsson G.

J Invest Dermatol. 2015 Jul;135(7):1820-1828. doi: 10.1038/jid.2015.61. Epub 2015 Feb 23.

48.

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.

Gansmo LB, Knappskog S, Romundstad P, Hveem K, Vatten L, Lønning PE.

Int J Cancer. 2015 Jul 1;137(1):96-103. doi: 10.1002/ijc.29358. Epub 2014 Dec 10.

49.

Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649).

Knappskog S, Gansmo LB, Dibirova K, Metspalu A, Cybulski C, Peterlongo P, Aaltonen L, Vatten L, Romundstad P, Hveem K, Devilee P, Evans GD, Lin D, Van Camp G, Manolopoulos VG, Osorio A, Milani L, Ozcelik T, Zalloua P, Mouzaya F, Bliznetz E, Balanovska E, Pocheshkova E, Kučinskas V, Atramentova L, Nymadawa P, Titov K, Lavryashina M, Yusupov Y, Bogdanova N, Koshel S, Zamora J, Wedge DC, Charlesworth D, Dörk T, Balanovsky O, Lønning PE.

Oncotarget. 2014 Sep 30;5(18):8223-34.

50.

Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens.

Løes IM, Immervoll H, Angelsen JH, Horn A, Geisler J, Busch C, Lønning PE, Knappskog S.

Tumour Biol. 2015 Feb;36(2):1003-13. doi: 10.1007/s13277-014-2711-5. Epub 2014 Oct 16.

Supplemental Content

Loading ...
Support Center